April 24, 2007 - GE Healthcare recently announced it has received clearance from the FDA for the company's next-generation volume PET/CT application, PET VCAR (Volume Computer-Assisted Reading), created to help clinicians diagnose, stage, treat and monitor tumors and other lesions in the body.

PET VCAR offers several workflow enhancements for both single- and multi-exam review, including exam-to-exam auto-registration, tumor segmentation and quantification, and multi-planar image review.

The FDA clearance includes a GE-patented Interactive Data Analysis (IDA) tool, which allows physicians to systematically track treatment over time and quantitatively interpret a patient's response to therapy. The new IDA capability reportedly facilitates informed, objective treatment decision-making by automating several previously manual processes and presenting data in an organized, user-configurable format.


Related Content

News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
arrow
News | Prostate Cancer

January 5, 2024 — Perspective Therapeutics, Inc., announced that it has entered into a patent license agreement with ...

Time January 05, 2024
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
Subscribe Now